Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 7/20 | 0.40 |
| ▸ | MAPK3 | P27361 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.33 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.33 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1640679 | 0.93 | P2RY12 (0.46) | P2RY12MAPK1MAPK3KDM4ESMN1; SMN2 | |
| SCHEMBL1639029 | 0.93 | P2RY12 (0.42) | P2RY12MAPK1MAPK3KDM4ESMN1; SMN2 | |
| SCHEMBL1639046 | 0.92 | P2RY12 (0.41) | P2RY12MAPK1MAPK3KDM4ESMN1; SMN2 | |
| SCHEMBL1640529 | 0.92 | P2RY12 (0.46) | P2RY12SMN1; SMN2TP53MAPTHTR3A | |
| SCHEMBL1640850 | 0.91 | P2RY12 (0.44) | P2RY12TP53MAPTHTR3A | |
| SCHEMBL1639633 | 0.90 | ROCK2 (0.40) | P2RY12MAPK1KDM4EALDH1A1HPGD | |
| SCHEMBL1640660 | 0.90 | P2RY12 (0.40) | P2RY12SMN1; SMN2GAATP53MAPT | |
| SCHEMBL1639568 | 0.88 | P2RY12 (0.39) | P2RY12KDM4ESMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL1640854 | 0.88 | P2RY12 (0.44) | P2RY12MAPK1MAPK3KDM4ESMN1; SMN2 | |
| SCHEMBL1639146 | 0.85 | P2RY12 (0.52) | P2RY12KDM4ESMN1; SMN2ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2094272-B1 | NITROGEN CONTAINING SUBSTITUTED HETEROCYCLES AS PLATELET ADP RECEPTOR INHIBITORS | PORTOLA PHARM INC (US) | 2014-03-26 | — | — | EP | claimed |
| US-7834023-B2 | Substituted dihydroquinazolines as platelet ADP receptor inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2010-11-16 | — | — | US | claimed |
| EP-2094272-A2 | NITROGEN CONTAINING SUBSTITUTED HETEROCYCLES AS PLATELET ADP RECEPTOR INHIBITORS | Portola Pharmaceuticals, Inc. (US) | 2009-09-02 | — | — | EP | claimed |
| US-20080132499-A1 | PLATELET ADP RECEPTOR INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2008-06-05 | — | — | US | claimed |
| WO-2008036843-A2 | NITROGEN CONTAINING SUBSTITUTED HETEROCYCLES AS PLATELET ADP RECEPTOR INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2008-03-27 | — | — | WO | claimed |
| EP-2094272-B1 | NITROGEN CONTAINING SUBSTITUTED HETEROCYCLES AS PLATELET ADP RECEPTOR INHIBITORS | PORTOLA PHARM INC (US) | 2014-03-26 | — | — | EP | disclosed |
| EP-2094272-B1 | NITROGEN CONTAINING SUBSTITUTED HETEROCYCLES AS PLATELET ADP RECEPTOR INHIBITORS | PORTOLA PHARM INC (US) | 2014-03-26 | — | — | EP | disclosed |
| US-20110098247-A1 | Substituted Dihydroquinazolines as Platelet ADP Receptor Inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2011-04-28 | — | — | US | disclosed |
| US-20110098247-A1 | Substituted Dihydroquinazolines as Platelet ADP Receptor Inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2011-04-28 | — | — | US | disclosed |
| US-20110098247-A1 | Substituted Dihydroquinazolines as Platelet ADP Receptor Inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2011-04-28 | — | — | US | disclosed |
| US-7834023-B2 | Substituted dihydroquinazolines as platelet ADP receptor inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2010-11-16 | — | — | US | disclosed |
| US-7834023-B2 | Substituted dihydroquinazolines as platelet ADP receptor inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2010-11-16 | — | — | US | disclosed |
| US-7834023-B2 | Substituted dihydroquinazolines as platelet ADP receptor inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2010-11-16 | — | — | US | disclosed |
| EP-2094272-A2 | NITROGEN CONTAINING SUBSTITUTED HETEROCYCLES AS PLATELET ADP RECEPTOR INHIBITORS | Portola Pharmaceuticals, Inc. (US) | 2009-09-02 | — | — | EP | disclosed |
| US-20080132499-A1 | PLATELET ADP RECEPTOR INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2008-06-05 | — | — | US | disclosed |
| US-20080132499-A1 | PLATELET ADP RECEPTOR INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2008-06-05 | — | — | US | disclosed |
| US-20080132499-A1 | PLATELET ADP RECEPTOR INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2008-06-05 | — | — | US | disclosed |
| WO-2008036843-A2 | NITROGEN CONTAINING SUBSTITUTED HETEROCYCLES AS PLATELET ADP RECEPTOR INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2008-03-27 | — | — | WO | disclosed |
| WO-2008036843-A2 | NITROGEN CONTAINING SUBSTITUTED HETEROCYCLES AS PLATELET ADP RECEPTOR INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2008-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098247-A1 | Substituted Dihydroquinazolines as Platelet ADP Receptor Inhibitors | TBXA2R, F2R, PTGER1 | P2RY12 120/4885MAPK1 562/4885MAPK3 2351/4885 |
| US-20080132499-A1 | PLATELET ADP RECEPTOR INHIBITORS | TBXA2R, PTAFR, PLAT | P2RY12 20/4885MAPK1 3800/4885MAPK3 3012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.